Eradication of Disseminated Lymphomas with CpG-DNA Activated T Helper Type 1 Cells from Nontransgenic Mice

Oliver Egeter, 2 Ralph Mocikat, 2,3 Kamran Ghoreschi, Andreas Dieckmann, and Martin Röcken 3

Department of Dermatology and Allergology, Ludwig-Maximilians-University, 80337 Munich [O. E., K. G., M. R.], and GSF-Institut für Molekulare Immunologie, 81377 Munich [A. D., R. M.], Germany

Abstract

Various evidence suggests that adoptive transfer of polyclonal, tumor-specific, IFN-γ-producing CD4+ T cells [T helper type 1 (Th1) cells] should be highly efficient for tumor immune therapy. However, this approach could not be tested because very few MHC class II-restricted tumor peptides have been defined. Here we show that stimulation of freshly isolated T helper cells with syngeneic tumor cells and antigen-presenting cells in the presence of immunostimulatory CpG DNA allows the generation of large numbers of strongly polarized, tumor-specific Th1 cells within 3 weeks of culture, even when T helper cells were derived from tumor-bearing mice. A single injection of $0.5 \times 10^5$ A20-specific Th1 cells even eradicated disseminated A20 lymphomas and provided lifelong protection without inducing autoimmune disease. The therapy was largely independent of CD8+ cells but required IFN-γ and CD40-CD40L interactions, suggesting that tumor-specific Th1 cells eradicate established tumors by activating proinflammatory macrophages.

Introduction

Active immunization with tumor antigens may induce inflammatory “autoimmune” responses against MHC class I-restricted tumor epitopes and protect against a large variety of tumors in mice and probably also in humans (1-3). Active immunization can even be used for tumor therapy, but the therapeutic efficacy is still limited. Loading dendritic APCs4 with total tumor extracts or peptides, modifying tumor cells with cytokines or costimulatory molecules, or stimulating T cells through CD28/CTLA-4 enhances the efficiency of antitumor vaccines but increases the risk of inducing autoimmune disease (1-3).

Recent insights into the crucial role of CD4+ T cells in orchestrating antitumor immunity (4-7) and the power of adoptively transferred IFN-γ-producing Th1 cells in specifically destroying targeted tissues (8) suggest that adoptive transfer of tumor-specific Th1 cells is feasible and may promise effective tumor therapy. However, only a few MHC class II-restricted tumor peptide epitopes have been characterized to date (9), a fact that has strongly impaired the exact analysis of tumor-specific CD4+ T cells, IFN-γ-producing Th1 cells, and IL-4-producing Th2 cells in tumor immunity. Generation of tumor-specific Th1 cell clones in vitro (7) or transfection of tumors with antigens recognized by T-cell receptor-transgenic lymphocytes from healthy mice (10) allowed to address some important questions, but these systems did not analyze the therapeutic potential of naturally occurring, tumor-reactive Th1 and Th2 cells or the properties of tumor-specific T cells occurring in tumor-bearing animals.

Because immunostimulatory CpG ODNs promote maturation of APCs and induce the expression of costimulatory molecules and the production of IL-12 (11-13), they should be useful as an in vitro adjuvant for the rapid generation of tumor-specific Th1 cells. Here we report that immunostimulatory CpG ODN 1668 allowed us to generate large amounts of tumor-specific Th1 and Th2 cells within 3 weeks of culture, surprisingly even when CD4+ T cells were isolated from mice with advanced tumors. Adoptive transfer of these tumor-specific Th1 cells efficiently eradicated even established tumors in a CD40L- and IFN-γ-dependent fashion, whereas in vitro-generated, IL-4-producing Th2 cells prolonged survival but ultimately failed to cure animals.

Materials and Methods

Media and Reagents. A20 lymphoma cells, MPC11 plasmacytoma cells, and BiV trioma cells were cultured in RPMI 1640 supplemented with 5% FCS, 2-mercaptoethanol, and 2 mM glutamine (Biochrom, Berlin, Germany) at 37°C in a humidified atmosphere with 5% CO2. BiV trioma cells are hybrids of the A20 lymphoma and the 2.4G2 hybridoma specific for the receptors FcγRII/III. Vaccination with BiV trioma cells that express the tumor idiotype as an immunoglobulin half molecule attached to the APC-binding arm confers efficient immunity against the wild-type tumor (14). T-cell lines were cultured in DMEM supplemented with 10% FCS and 2-mercaptoethanol. Phosphothioate-modified CpG ODN 1668 (5’-TCCATGACGTTCCTGATGCT-3’) was from MWG (München, Germany). The IL-4 and IFN-γ content of culture supernatants was determined using commercially available ELISA Abs (PharMingen, Hamburg, Germany).

T-cell Lines. CD4+ T cells were derived from spleen and lymph node cells from mice immunized twice with 105 BiV trioma cells (14) or from mice with a large tumor burden (>day 30). These CD4+ T cells were enriched by negative selection over Biotex T-cell columns (TEBU, Frankfurt, Germany) to 95% purity. No CD8+ T cells were detectable by fluorescence-activated cell-sorting analysis. The CD4+ T cells (2 × 106) were stimulated in vitro 96-well round-bottomed tissue culture plates in the presence of irradiated (30 Gy) T-cell-depleted syngeneic spleen cells, 3 × 106 irradiated (90 Gy; from a 13Cs source) A20 tumor cells, CpG ODN 1668 (0.2 μg), IL-2 (5 units/ml; a gift from Chiron, Ratingen, Germany), and anti-IL-4 mAb 11B11 (10 μg/ml) to generate Th1 lines. To generate Th2 cell lines, IL-4 (1000 units/ml) was added to the culture instead of anti-IL-4 mAb. Recombinant IL-4 was derived from X63Ag-653 cells (a gift of F. Melchers; Basel Institute of Immunology, Basel, Switzerland). On day 10, cells were purified on a Ficoll gradient and restimulated as described on day 1. The cells were expanded for another 7 days, and on day 20, these >95% pure CD4+ T cells were used for adoptive transfer, and a fraction of these cells was used for functional characterization.

To generate anti-A20 CD8+ T cell lines, 4 × 106 spleen and lymph node cells from trioma-vaccinated mice were suspended in medium, seeded in 24-well plates, and mixed with 106 irradiated (100 Gy) A20 cells. A restimulation followed at day 6 with an additional 107 naïve syngeneic spleen cells (irradiated at 30 Gy). On day 8, 30 units/ml IL-2 were added. One day later, T-cell reactivity against irradiated A20 or MPC11 cells was determined by [3H]thymidine incorporation or by measuring granulocyte macrophage colony-stimulating factor.
phage colony-stimulating factor secretion in an ELISA. Before in vivo application, the remaining CD4+ T cells were depleted by immunomagnetic separation. This population was 99% CD8+.

**Animal Experiments.** Mice were purchased from Bommice (Ry, Denmark). All experiments were done with groups of five or six female animals. For immunization, mice were injected i.p. with 10⁵ BiV trioma cells twice in a 3-week interval (14). In the tumor prevention experiments shown, the animals received a lethal A20 tumor dose (3 × 10⁵ cells) together with 5 × 10⁵ CD4+ T cells i.p. To evaluate therapy of a preexisting tumor burden, mice were challenged first with a lethal i.v. A20 inoculum (3 × 10⁵ cells) and treated with 5 × 10⁵ Th1 cells i.v. on day 5 or 7. Mice were euthanized when signs of tumor growth became visible. CD8+ T cells were depleted in vivo by five i.p. injections of 0.5 mg of the anti-CD8 mAb RmCD8.2 (14) every 3–8 days starting 4 days before Th1 cell treatment. The anti-CD40L mAb MR-1 (16) was given at a dose of 0.25 mg i.p. on day 0, 2, 4, and 8 of Th1 therapy. All animal experiments were performed at least twice. Statistical survival analyses were done using the log-rank test.

**Results and Discussion**

**Rapid in Vitro Generation of Tumor-specific Th1 Cells Using CpG ODN 1668.** To study the in vitro generation of tumor-specific Th1 cells and adoptive transfer of Th1 cells in antitumor immunity, we selected the poorly immunogenic A20 B-cell lymphoma, one of the most well-established lymphoma models in mice (14, 18). Highly purified CD4+ T cells were first derived from BALB/c mice immunized with a hybrid cell line of the A20 lymphoma and the 2.4G2 hybridoma (BiV trioma; Ref. 14) and were stimulated in vitro with CpG ODN 1668. As shown in Fig. 1A, the expansion of A20-specific Th1 cells was significantly increased in the presence of anti-IL-4 mAb 11B11 alone (left) or in the presence of anti-IL-4 mAb 11B11 and CpG ODN 1668 (right). The specific cytokine pattern of the Th1 cells was given in B. Cytokine production by A20-specific (B) Th1 and (C) Th2 cell lines derived from BALB/c mice immunized with BiV trioma cells. The Th1 and Th2 cell lines were generated as described in “Materials and Methods.” For determination of the cytokine pattern, Th cell lines were stimulated overnight in the presence of APCs with or without irradiated A20 lymphoma or MPC11 plasmacytoma cells. The IL-4 and IFN-γ content in the 24-h culture supernatant was determined by ELISA. D, antigen-specific cytotoxicity and Ca²⁺ independence of A20-reactive Th1 cell lines. Th1 cells form BiV trioma-immunized BALB/c mice were generated as described in A, and the lysis of the different target cells was measured using the JAM test. Cytotoxicity tests were performed in the presence (closed symbols) or absence (open symbols) of 1 mM EGTA and 1.5 mM MgCl₂. Experiments were performed in triplicates. Two of three independent experiments are shown.
IL-4 mAb provided 12–70 times more CD4+ cells than IL-4 when exposed to A20 cells. APCs and irradiated A20 lymphoma cells. Using the immunostimulatory CpG ODN 1668 as an in vitro adjuvant (12), this procedure provided 3–6 × 10^6 CD4+ T cells (>99% CD4+) per mouse within 3 weeks. Cultures initiated in the presence of CpG ODNs and anti-IL-4 mAb provided 12–70 times more CD4+ T cells than cultures initiated in the absence of CpG ODNs (Fig. 1A). These CD4+ T cells produced about 50 times more IFN-γ than IL-4 when exposed to A20 cells. No specific cytokine production was observed when the cells were exposed to syngeneic APCs or to an unrelated lymphoma, MPC11 (Fig. 1B). Because these CD4+ T cells specifically killed A20 lymphomas in vitro in a Ca^2+-independent fashion (Fig. 1D), these cells were A20-specific Th1 cells.

Adoptive Transfer of A20-specific Th1 Cells Provides Protection against A20 Lymphomas. Adoptive transfer of 0.5 × 10^6 A20-specific Th1 cells (20 × 10^6 cells/kg bodyweight) protected 80–100% of mice against a simultaneous challenge with a lethal dose of i.p. or i.v. applied A20 lymphoma cells (Fig. 2A). Adoptive transfer of Th1 cells was more efficient than adoptive transfer of A20-specific CD8+ cytotoxic T-cell lines (Fig. 2B). Moreover, Th1 cells protected even CD8-depleted mice from the A20 lymphoma (Fig. 2A), suggesting that CD8-independent mechanisms play an important role in Th1 cell-mediated tumor protection. The treatment provided lifelong protection (up to 2 years), and no tumor cells were detected in spleen or bone marrow by fluorescence-activated cell-sorting analyses. More importantly, no dormant tumor cells were detectable in long-term cultures from spleen or bone marrow cells of Th1 cell-treated mice (data not shown).

The in vitro data (Fig. 1B) suggested that A20-reactive Th1 cells predominantly recognized tumor-associated antigens. Because adoptive transfer of autoreactive T cells can induce severe autoimmune disease (8, 13), and because the tumor-reactive Th1 lines generated in

Fig. 2. In vitro-generated, A20-specific CD4+ Th1 cells provide better protection than A20-specific CD8+ cytotoxic T-cell lines. A, tumor protection by adoptive transfer of CD4+ Th1 cells. BALB/c mice received a lethal i.p. A20 cell dose (3 × 10^5 cells) and 5 × 10^6 A20-specific Th1 cells. The tumor control group received only 3 × 10^6 A20 cells. CD8+ T cells were depleted with mAb RnCD8.2 (B), tumor protection by adoptive transfer of CD8+ T cell lines. BALB/c mice received a lethal i.p. A20 cell dose (3 × 10^5 cells) and 5 × 10^6 A20-specific CD8+ cytotoxic T cells. The tumor control group received only 3 × 10^6 A20 cells.

Adoptive Transfer of A20-specific Th1 Cells Eradicates Disseminated Lymphomas by a CD40L- and IFN-γ-dependent Mechanism. Adoptive transfer of A20-reactive Th1 cells was safe and effective in preventing tumors. Therefore, we analyzed the cells’...
capacity in the therapy of established tumors. Within 5 days, injection of $0.3 \times 10^6$ A20 lymphoma cells establishes a tumor burden that responds only to the most efficient immunization protocols (14, 18), and in the following 3 days, the splenic tumor burden increased again at least 100-fold (analyzed in four mice). When given 5 days or even 7 days after establishing the lymphoma, adoptive transfer of $0.5 \times 10^6$ A20-reactive Th1 cells still cured up to 70% of the animals (Fig. 3A). The therapy provided long-lasting immunity because 10 of 10 mice rejected a lethal A20 rechallenge on day 100 or 125. Effective therapy was dependent on Th1 cell recognition of tumor-associated peptides because identically generated, ovalbumin-specific Th1 cells provided no protection (Fig. 3A). Importantly, the therapy required a high IFN-\(\gamma\)-IL-4 ratio. Th0 cells producing both IL-4 and IFN-\(\gamma\) as well as IL-4-producing Th2 cells, which can induce strong immunoglobulin production and attract eosinophils (6, 7), significantly prolonged survival. However, all IL-4-producing Th0 and Th2 cell lines tested were unable to cure mice of the lymphoma (shown for Th2 cells in Figs. 1C and 3A). The high therapeutic efficacy of A20-reactive Th1 cells was surprising because it was shown that naive tumor-specific CD4\(^+\) T cells from transgenic animals are immediately silenced and provide no protection when transferred into tumor-bearing mice (10). In contrast, transfer of tumor-specific Th1 cell lines established persistent, A20-specific Th1 responses in vivo because spleen cells from Th1-treated mice produced large amounts of IFN-\(\gamma\) when stimulated directly ex vivo with A20 cells (Fig. 3B). It is not known whether this IFN-\(\gamma\) was produced by CD4\(^+\) or CD8\(^+\) T cells and whether the responding Th1 cells are derived from the donor or the recipient. However, a series of unrelated experiments suggests that most of the IFN-\(\gamma\) is derived from the transferred Th1 cells.\(^5\)

An increasing amount of data shows that CD4\(^+\) T cells play a pivotal role in orchestrating tumor immune responses. Their in vivo activity against MHC class II-positive and MHC class II-negative tumors has been associated with their capacity to provide help for CD8-mediated killing (19), induce IFN-\(\gamma\)-dependent monocyte/macrophage-mediated cytotoxicity (4, 7), or induce production of antitumor immunoglobulin by B cells (5). All three mechanisms are dependent on CD40-CD40L interactions (16, 20). To determine the contribution of CD40-CD40L interactions to Th1 cell-mediated therapy, we blocked this interaction in Th1 cell-treated animals with the anti-CD40L mAb MR-1. This mAb completely abolished the capacity of anti-A20 Th1 cells to cure established lymphomas (Fig. 3C). Although other models of CD40-mediated tumor immunity suggest a crucial role for tumor-specific CD8\(^+\) T cells (18) and for Abs directed against tumor epitopes (5), these two modes of antitumor immunity seem to be of minor importance in our model. Transfer of A20-

\(^5\) O. Egeter and M. Röcken, unpublished data.
reactive Th1 cells controlled the tumor in about 3 days, a time too short to provide help for immunoglobulin production or cytotoxic T-cell responses. Consequently, injection of anti-CD8 mAb barely influenced the efficacy of Th1 cell-mediated tumor therapy (data not shown), and significant Ab titers against A20 cells could not be detected (data not shown). Thus, Th1 cells may kill A20 cells through direct CD40-CD40L interactions or indirect, IFN-γ-dependent mechanisms (4, 7). To address the role of Th1 cell-derived IFN-γ in adoptive tumor therapy, we inhibited IFN-γ with the XMG-1.2 mAb in vivo according to a protocol that inhibits Th1 cell-mediated protection in murine leishmaniasis (21). The therapeutic efficacy of A20-reactive Th1 cells was completely abrogated (Fig. 3D), strongly suggesting that adoptive therapy with Th1 cells was dependent on both CD40-CD40L interactions and IFN-γ.

Th1 cells express CD40L (14, 20), and A20-reactive Th1 cells kill A20 lymphomas in vitro in a Ca<sup>2+</sup>-independent fashion (Fig. 1D). Because binding of CD40 may lead to direct tumor elimination (18), our findings can be interpreted as direct killing of the A20 lymphoma by CD40-binding Th1 cells. However, the data showing that A20-specific Th0 cells producing both IL-4 and IFN-γ were ineffective in curing mice from established lymphomas and that anti-IFN-γ mAb abolished the therapeutic effect strongly suggest that other mechanisms were critical for tumor elimination by Th1 cells. Signaling through CD40 and IFN-γ activates APCs such as macrophages and primes these cells for initiating inflammatory immune responses (4, 7, 17, 21–23). Because this priming of APCs is inhibited by IL-4 or anti-IFN-γ, the IL-4-producing Th2 or Th0 cells may have inhibited tumor elimination by suppressing the development of proinflammatory macrophages, a mechanism originally described for inflammatory autoimmune and parasitic diseases (8, 21).

**CpG ODNs Allow the Rapid Generation of Tumor-specific and Protective Th1 Cells from Mice with Large Tumor Burden.** In the experiments described above, A20-reactive Th1 cells were derived from preimmunized animals. To mimic a situation more close to the clinic, we investigated whether anti-A20-reactive Th1 cells could also be generated from mice that had to be euthanized because of tumor wasting (>day 30). In some models, tumors elminate or silence (10) tumor-reactive T cells, whereas in other transgenic models, tumor-reactive T cells could be readily derived from tumor-bearing animals (24). We first analyzed whether A20-reactive CD4<sup>+</sup> T cells could be detected in lymphoma-bearing mice. Surprisingly, using CpG ODNs, we could readily generate A20-specific, cytotoxic T cells, even from animals with a large tumor burden (Fig. 4A). Whereas few or no tumor-specific Th1 cells were obtained from cultures initiated in the absence of CpG ODNs (Fig. 4B), the addition of CpG ODN 1668 as an in vitro adjuvant allowed us to generate large numbers of A20-reactive Th1 cells even from animals with large tumors. These Th1 cells specifically recognized A20 lymphomas and produced the same cytokine pattern as Th1 cells derived from immunized animals (Fig. 4C). Importantly, these Th1 cells also rejected A20 lymphomas (Fig. 4D), although preliminary results suggest that Th1 cell lines from tumor-bearing animals may be less effective than Th1 cells derived from BiV trioma-immunized animals (compare Figs. 2A and 4D).

**Concluding Remarks.** The data presented show that CpG ODNs provide a unique in vitro adjuvant to rapidly generate highly tumor-specific Th1 cells, even from mice with a large tumor burden. The Th1 cells killed A20 lymphomas in a Ca<sup>2+</sup>-independent fashion, and adoptive transfer of syngeneic, A20-specific Th1 cells was highly efficient in tumor prevention and even in the therapy of advanced A20 lymphomas (day 7). The therapeutic effect was largely independent of CD8<sup>+</sup> T cells and was strictly dependent on tumor-specific cells with a Th1-phenotype, a high IFN-γ:IL-4 ratio, CD40-CD40L interactions, and IFN-γ. These data suggest that Th1 cells eradicated the established tumors predominantly through an indirect mechanism. Because Th1 cells control intracellular pathogens through the activation of macrophages (21), and because activation of macrophages by IFN-γ was recently shown to be important in tumor prevention (7), it is likely that Th1 cells use this CD40L- and IFN-γ-dependent mode of cell-mediated immunity for the elimination of established tumors.

Surprisingly, these mechanisms of tumor elimination differ substantially from those recently reported by Nishimura et al. (25), who found that both Th1 and Th2 cells are equally effective in tumor therapy. Moreover, in the system reported by Nishimura et al., Th1 cells strictly required tumor-specific CD8<sup>+</sup> T cells to eradicate the tumor and killed lymphoma cells exclusively in a Ca<sup>2+</sup>-dependent fashion. Importantly, these two systems differ profoundly in their approach. Nishimura et al. used T-cell receptor-transgenic Th cells directed against OVA-transfected tumor cells. In contrast, we used no artificial rejection antigen and derived tumor-specific Th1 cells from nontransgenic, tumor-bearing animals by stimulating CD4<sup>+</sup> T cells in the presence of CpG ODNs. Establishing whether these fundamentally different modes of tumor immunity are determined by the source of the Th1, by the immunostimulatory ODNs, or by the routes of tumor application (s.c. versus i.p. or i.v.) may provide important data for the development of tumor therapies.

Importantly, tumor elimination was never associated with autoaggressive disease, showing that tolerance to self-proteins, whose expression pattern is shared between A20 cells and normal tissue, was not broken, even when A20-specific Th1 cells were derived from trioma-immunized animals. Because tumor-reactive Th1 cells can be generated not only from immunized animals but also from tumor-bearing animals, adoptive transfer of tumor-specific Th1 cells may provide a novel and safe therapeutic approach for hematopoietic tumors and perhaps even solid tumors.

**Acknowledgments**

We thank Dr. G. Hoffmann-Fezer for histological analyses and B. von Restorff, H. Jennis, J. Jasny, and U. Bamberg for excellent technical assistance. We are grateful to Drs. S. D. Schendel and B. Frankenberg (GSF-Institute, Munich, Germany), A. Knuth (Ludwig-Institute, Frankfurt, Germany), J.-C. Cerottini (Ludwig-Institute, Lausanne, Switzerland), and R. Offringa (Dept. of Immunohematology, Universität Leiden, the Netherlands) for critically reviewing the manuscript; Drs. K. Heeg and H. Wagner (Technical University, Munich, Germany) for help with the CpG ODN experiments; R. Noelle (Dartmouth College, Hanover, NH) for the MR-1 mAb; and J. Louis (Institute of Biochemistry, University of Lausanne, Lausanne, Switzerland) for XMG-1.2 mAb.

**References**


Eradication of Disseminated Lymphomas with CpG-DNA Activated T Helper Type 1 Cells from Nontransgenic Mice

Oliver Egeter, Ralph Mocikat, Kamran Ghoreschi, et al.


Updated version

Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/60/6/1515

Cited articles

This article cites 22 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/60/6/1515.full#ref-list-1

Citing articles

This article has been cited by 11 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/60/6/1515.full#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/60/6/1515.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.